A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, randomised, double-blind trials of secukinumab (SCULPTURE, ERASURE/FIXTURE, TRANSFIGURE, GESTURE, FUTURE 2 and MEASURE 2) in a total of 1,872 patients.

Findings were presented at the World Congress of Dermatology (WCD) in Milan.

“These data across multiple manifestations of psoriatic disease including persistent manifestations, psoriatic arthritis as well as ankylosing spondylitis, provide much needed, additional guidance for prescribing dermatologists who want to treat their patient in a comprehensive way,” says Richard Langley, Professor of Dermatology, Dalhousie University, Halifax, Nova Scotia, Canada.

 Another abstract, “Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients over 5 years,” also presented at WCD, investigated the immunogenicity of secukinumab treatment up to 5 years in two phase III extension studies (CAIN457A2304 and CAIN457A2307) in patients with moderate to severe plaque psoriasis. In total, 1821 patients entered the extension studies.